Impact of Clinicopathological and Institutional Factors on the Clinical Courses of Patients With Localized Prostate Cancer Initially Managed by Active Surveillance: An Analysis of Nationwide Real‐World Data From Japan
Authors:
- Mizuki OnozawaMOMizuki Onozawa
- Masaki ShiotaMasaki Shiota
- Taketo KawaiTKTaketo Kawai
- Shinichi SakamotoShinichi Sakamoto
- Yoshiyuki YamamotoYYYoshiyuki Yamamoto
- Satoru TaguchiSTSatoru Taguchi
- Tohru NakagawaTNTohru Nakagawa
- Shiro HinotsuSHShiro Hinotsu
- Jun MiyazakiJMJun Miyazaki
- Japan Study Group of Prostate Cancer (J-CaP)J(Japan Study Group of Prostate Cancer (J-CaP)
Open Access
- 14 September 2026
- journal article
- research article
- Published by Wiley in International Journal of Urology
- Vol. 33 (9) , e70642
Abstract
Objectives: To investigate active surveillance (AS) continuation rates and associated clinical and institutional factors in Japanese patients with localized prostate cancer. Methods: We retrospectively analyzed 989 patients with localized prostate cancer from 92 institutions who initiated AS between 2016 and 2018. Institutions were categorized into three groups based on AS uptake for low‐risk disease. Discontinuation triggers and subsequent treatments were examined. Results: Median age was 70 years; 66.2%, 26.0%, and 7.8% of patients had low‐, intermediate‐, and high‐risk disease, respectively. Over a median follow‐up of 3.4 years, 47.0% discontinued AS (median AS continuation time: 3.0 years; 5‐year AS continuation rate: 33.7%). Multivariable analysis showed that ≥ 2 comorbidities, ≥ 3 positive biopsy cores, and T2b–c stage were associated with restricted mean continuation time differences (RMCTDs) of −0.6, −0.6, and −0.8 years, respectively (all p < 0.05). Conversely, intermediate‐ and high‐AS uptake institutions had significantly longer adjusted RMCTD (1.0 and 1.1 years, respectively; both p < 0.001). Triggers for discontinuation were more often multifaceted in high‐AS uptake institutions (39.1%) compared with low‐ or intermediate‐AS uptake institutions (16.2% and 15.1%, respectively). After discontinuation, 36.5%, 39.2%, and 24.3% of patients received prostatectomy, radiotherapy, and hormonal therapy, respectively. With advancing age, the proportion of patients whose AS was discontinued due to PSA elevation increased, as did the rate of subsequent hormonal therapy. Conclusions: In Japanese real‐world practice, AS continuation was limited. Beyond clinicopathological factors, institutional strategies for localized prostate cancer played a significant role in treatment choices following AS.Keywords
This publication has 27 references indexed in Scilit:
- Time Trends and Variation in the Use of Active Surveillance for Management of Low-risk Prostate Cancer in the USJAMA Network Open, 2023
- A randomized controlled trial evaluating the effect of low-dose chlormadinone in patients with low-risk prostate cancer: PROSAS studyJapanese Journal of Clinical Oncology, 2021
- Active Surveillance of Grade Group 1 Prostate Cancer: Long-term Outcomes from a Large Prospective CohortEuropean Urology, 2020
- Long-Term Cancer Specific Anxiety in Men Undergoing Active Surveillance of Prostate Cancer: Findings from a Large Prospective CohortJournal of Urology, 2018
- Factors Influencing Men's Choice of and Adherence to Active Surveillance for Low-risk Prostate Cancer: A Mixed-method Systematic ReviewEuropean Urology, 2018
- Impact of 5α-Reductase Inhibitors on Disease Reclassification among Men on Active Surveillance for Localized Prostate Cancer with Favorable FeaturesJournal of Urology, 2018
- A Decade of Active Surveillance in the PRIAS Study: An Update and Evaluation of the Criteria Used to Recommend a Switch to Active TreatmentEuropean Urology, 2016
- Long-term Results of Active Surveillance in the Göteborg Randomized, Population-based Prostate Cancer Screening TrialEuropean Urology, 2016
- Extended Followup and Risk Factors for Disease Reclassification in a Large Active Surveillance Cohort for Localized Prostate CancerJournal of Urology, 2015
- Five-year Nationwide Follow-up Study of Active Surveillance for Prostate CancerEuropean Urology, 2015